Humana Inc. (NYSE:HUM) Shares Acquired by Forsta AP Fonden

Forsta AP Fonden boosted its position in Humana Inc. (NYSE:HUM) by 2.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 25,200 shares of the insurance provider’s stock after purchasing an additional 500 shares during the period. Forsta AP Fonden’s holdings in Humana were worth $6,393,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Asset Dedication LLC raised its stake in shares of Humana by 73.5% in the 4th quarter. Asset Dedication LLC now owns 800 shares of the insurance provider’s stock worth $203,000 after buying an additional 339 shares in the last quarter. Matrix Asset Advisors Inc. NY purchased a new position in Humana in the 4th quarter worth about $1,674,000. Revolve Wealth Partners LLC acquired a new position in shares of Humana in the fourth quarter worth about $202,000. CKW Financial Group increased its position in shares of Humana by 90.9% in the fourth quarter. CKW Financial Group now owns 525 shares of the insurance provider’s stock worth $133,000 after acquiring an additional 250 shares in the last quarter. Finally, Pacer Advisors Inc. raised its holdings in shares of Humana by 58.5% during the fourth quarter. Pacer Advisors Inc. now owns 15,579 shares of the insurance provider’s stock valued at $3,953,000 after acquiring an additional 5,750 shares during the period. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Humana

In related news, insider Timothy S. Huval sold 3,703 shares of the stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the sale, the insider now owns 8,181 shares in the company, valued at approximately $2,096,463.06. This trade represents a 31.16 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.32% of the company’s stock.

Humana Stock Performance

Shares of HUM stock opened at $293.40 on Friday. Humana Inc. has a one year low of $213.31 and a one year high of $406.46. The firm has a 50-day moving average of $275.45 and a 200-day moving average of $303.03. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.76 and a quick ratio of 1.76. The company has a market cap of $35.33 billion, a P/E ratio of 25.99, a P/E/G ratio of 2.22 and a beta of 0.55.

Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, October 30th. The insurance provider reported $4.16 EPS for the quarter, beating the consensus estimate of $3.48 by $0.68. The business had revenue of $29.30 billion for the quarter, compared to the consensus estimate of $28.66 billion. Humana had a return on equity of 13.20% and a net margin of 1.18%. Equities research analysts forecast that Humana Inc. will post 16.11 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on HUM shares. Royal Bank of Canada reduced their price objective on Humana from $400.00 to $265.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. UBS Group cut their price objective on shares of Humana from $380.00 to $250.00 and set a “neutral” rating on the stock in a research report on Friday, October 4th. Barclays increased their price objective on Humana from $253.00 to $255.00 and gave the company an “equal weight” rating in a report on Wednesday, January 22nd. KeyCorp started coverage on shares of Humana in a research note on Friday, October 11th. They set a “sector weight” rating for the company. Finally, Morgan Stanley lifted their target price on shares of Humana from $288.00 to $301.00 and gave the company an “equal weight” rating in a research report on Tuesday, December 17th. Nineteen investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $297.68.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.